REVIEW

1146 Advanced glycation end products: Key mediator and therapeutic target of cardiovascular complications in diabetes
   Bansal S, Burman A, Tripathi AK

1163 Dysglycemia and arrhythmias
   Sun DK, Zhang N, Liu Y, Qiu JC, Tse G, Li GP, Roever L, Liu T

1178 Gestational diabetes mellitus and COVID-19: The epidemic during the pandemic
   Mendez Y, Alquing Radilla LA, Delgadillo Chabolla LE, Castillo Cruz A, Luna J, Surani S

MINIREVIEWS

1194 Ten-year review of trends in children with type 1 diabetes in England and Wales
   Ng SM, Soni A

1202 Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus: A mini review
   See KC

1212 Diabetes mellitus as a consequence of acute severe pancreatitis: Unraveling the mystery
   Manrai M, Singh AK, Birda CL, Shah J, Dutta A, Bhadada SK, Kochhar R

1226 Advances in cardiovascular-related biomarkers to predict diabetic peripheral neuropathy
   Cheng MK, Guo YF, Kang XN, Zhang L, Wang D, Ren HH, Yuan G

ORIGINAL ARTICLE

Basic Study

1234 Potential role of microRNA-503 in Icariin-mediated prevention of high glucose-induced endoplasmic reticulum stress
   Su BL, Wang LL, Zhang LY, Zhang S, Li Q, Chen GY

1249 Impact of bariatric surgery on glucose and lipid metabolism and liver and kidney function in food-induced obese diabetic rats
   Long H, Zhao L, Xiao ZS, Li SX, Huang QL, Xiao S, Wu LL

Case Control Study

1259 Risk and predictors of severity and mortality in patients with type 2 diabetes and COVID-19 in Dubai
## Contents

### Retrospective Study

1271  Conbercept combined with laser photocoagulation in the treatment of diabetic macular edema and its influence on intraocular cytokines  
  
  Zhan HQ, Zhou JL, Zhang J, Wu D, Gu CY

### Observational Study

1280  Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients  
  
  Huang XM, Zhong X, Du YJ, Guo YY, Pan TR

### META-ANALYSIS

1289  Prognostic role of metformin in diabetes mellitus type 2 patients with hepatocellular carcinoma: A systematic review and meta-analysis  
  
  Cigrovski Berkovic M, Giovanardi F, Mrzljak A, Lai Q

1301  New environmental factors related to diabetes risk in humans: Emerging bisphenols used in synthesis of plastics  
  

1314  Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports  
  
  Juneja D, Nasa P, Jain R, Singh O

### CASE REPORT

1323  Sequential treatment for diabetic foot ulcers in dialysis patients: A case report  
  
  Wang JJ, Yu YY, Wang PY, Huang XM, Chen X, Chen XG
ABOUT COVER
Editorial Board Member of World Journal of Diabetes, Samuel Trevino, PhD, Full Professor, Research Scientist, Clinical Biochemistry, University Autonomous of Puebla, Puebla 72000, Mexico. samuel_trevino@hotmail.com

AIMS AND SCOPE
The primary aim of World Journal of Diabetes (WJD, World J Diabetes) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJD mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

INDEXING/ABSTRACTING
The WJD is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJD as 4.2; IF without journal self cites: 4.1; 5-year IF: 4.5; Journal Citation Indicator: 0.69; Ranking: 51 among 145 journals in endocrinology and metabolism; and Quartile category: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yu-Xi Chen; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL
World Journal of Diabetes

ISSN
ISSN 1948-9358 (online)

LAUNCH DATE
June 15, 2010

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Lu Cai, Md. Shahidul Islam, Michael Horowitz

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
August 15, 2023

COPYRIGHT
© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/GerInfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
New environmental factors related to diabetes risk in humans: Emerging bisphenols used in synthesis of plastics

Rafael Moreno-Gómez-Toledano, María Delgado-Marín, Alberto Cook-Calvete, Claudia González-Cucharero, Nunzio Alcharani, Beatriz Jiménez-Guirado, Ignacio Hernandez, Rafael Ramirez-Carracedo, Laura Tesoro, Laura Botana, Sandra Sánchez-Esteban, Javier Diez-Mata, Jose Luis Zamorano, Ricardo J. Bosch, Carlos Zaragoza, Marta Saura

**Specialty type:** Endocrinology and metabolism

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report’s scientific quality classification**
- Grade A (Excellent): 0
- Grade B (Very good): B
- Grade C (Good): C, C
- Grade D (Fair): 0
- Grade E (Poor): 0

**P-Reviewer:** Belosludtseva NV, Russia; Lei XH, China; Zhao W, China

**Received:** March 28, 2023

**Peer-review started:** March 28, 2023

**First decision:** May 8, 2023

**Revised:** May 21, 2023

**Accepted:** June 5, 2023

**Article in press:** June 5, 2023

**Published online:** August 15, 2023

**Corresponding author:** Rafael Moreno-Gómez-Toledano, PhD, Assistant Professor, Postdoctoral Fellow, Research Scientist, Universidad de Alcalá, Department of Biological Systems/Physiology, Facultad de Medicina-Campus Universitario-C/19, Av. De Madrid, Km 33600, Alcalá de Henares 28871, Spain. r.morengomeztoledano@gmail.com

**Abstract**

**BACKGROUND**

Diabetes mellitus (DM) is one of the largest global health emergencies of the 21st century. In recent years, its connection with environmental pollutants, such as bisphenol A (BPA), has been demonstrated; consequently, new structurally similar molecules are used to replace BPA in the plastics industry (BPS, BPF and BPAF).

**AIM**

To carry out a systematic review to allow coherent evaluation of the state of the
art. Subsequently, a meta-analysis was performed to unify the existing quantitative data.

METHODS
Firstly, a systematic review was carried out, using the terms “(bisphenol) AND (Diabetes OR Hyperglycemia)”, to maximize the number of results. Subsequently, three authors analyzed the set of articles. Finally, a meta-analysis was performed for each BP, using RevMan software. In addition, funnel plots were developed to study publication bias.

RESULTS
The systematic analysis of the literature revealed 13 recent articles (2017–2023) related to the study paradigm. The qualitative analysis showed interesting data linking diabetes to the three most widely used substitute BPs in the industry: BPS, BPF and BPAF. Finally, the meta-analysis determined a positive relationship with BPS, BPF and BPAF, which was only statistically significant with BPS.

CONCLUSION
There is a need to apply the precautionary principle, regulating the use of new BPs. Therefore, replacing BPA with BPS, BPF or BPAF is unlikely to protect the population from potential health risks, such as DM.

Key Words: Bisphenol S; Bisphenol F; Bisphenol AF; Diabetes mellitus; Systematic review; Meta-analysis

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The present study analyzed the potential dangers that society faces with the replacement of bisphenol A (BPA) by new BPs. Thus, using PRISMA methodologies, a systematic review and meta-analysis of the relationship between new BPs and diabetes mellitus (DM) in humans was carried out. The results showed a positive relationship between BPS, BPF and BPAF and DM, which was statistically significant only with BPS. Consequently, new BPs could represent a health risk equivalent to that of BPA.


URL: https://www.wjgnet.com/1948-9358/full/v14/i8/1301.htm
DOI: https://dx.doi.org/10.4239/wjd.v14.i8.1301

INTRODUCTION
Diabetes mellitus (DM) is one of the largest global health emergencies of the 21st century[1]. The prevalence of DM in recent decades has increased substantially. In 1980, the number of people affected was around 108 million adults aged 20–79 years; currently, the prevalence is 10.5% of the world population (536 million people affected), and it is estimated that could increase to 12.2% in 2045 (783.2 million)[2]. DM risk factors include numerous environmental and/or genetic factors, including covariates such as age, weight, diet, and smoking[3]. Therefore, the idea that environmental pollutants could play a role in the development or progression of the disease is coherent. In the literature, there is evidence that suggests a possible relationship between DM and environmental pollutants[4].

Plastics are one of the main environmental pollutants that modern society faces. Thanks to their multiplicity of uses and low cost, plastics have become one of the main axes of modern industry. The central element of the plastics industry is bisphenol A (BPA); a monomer of epoxy resins and polycarbonates used as an additive and improver of the physical properties of different polymers[5]. In the mid-1970s, BPA was part, directly or indirectly, of all major American industries[6]. Currently, the production volume of plastics has increased from 2 million tons (in 1950) to 368 million tons in 2019[7]. Economic studies estimate that plastic production will double in the next 20 years[8].

In recent years the scientific community has highlighted the potential health risks associated with BPA exposure, related with numerous pathologies, such as hormonal alterations[9,10], DM[11], obesity[12], hypertension[13], chronic kidney disease/diabetic nephropathy[14,15] or even with disorders of embryonic development[16,17]. For this reason, the new emerging regulations limit the use of BPA in various contexts, such as baby products[18,19], thermal paper (used in purchase receipts)[20], or containers[21]. Consequently, industries are replacing BPA with substitute molecules with similar structure and molecular weight. The three most important molecules in the plastic industry are BPS, BPF and BPAF[22–24]. In terms of European legislation, BPA is the only monomer that has a harmonized EU classification as toxic to reproduction 1B, H360F (may damage fertility). However, BPS is self-classified under REACH (EU chemicals legislation) as toxic to reproduction 2 (H361F), and BPAF is self-classified as toxic to reproduction 1B (H360F)[25]. BPF has not been classified, but it also has the potential to induce reproductive toxicity[25], showing a hormonal activity as active
as BPA or BPS[22]. Despite the small number of publications exploring the possible effects of these new molecules on human health, their presence has already been detected in air, water, and food of many parts of the world[24,26-28].

The present study was a systematic review of the literature to allow a coherent evaluation of the state of the art. Subsequently, a meta-analysis was performed to unify the existing quantitative data. The primary outcome measures were serum/plasma or urinary BPs (except BPA) in relation to DM. The analysis was limited to humans and English language, but no restriction was applied in the academic search engines.

MATERIALS AND METHODS

Selection of studies
The study was conducted using the PRISMA guidelines[29,30] as a methodological basis. The main objective of the study was to identify and analyze the state of the art of the new bisphenols–diabetes paradigm. In recent years, the number of evidence related to BPA has increased; however, the new BPA substitute molecules continue to be relegated to the background in the literature, with a small amount of available evidence. For this reason, all those original studies that studied the possible implications of any BP (except for BPA), in the context of human populations, were selected. From the set of publications selected for the qualitative analysis, manuscripts with logistic regression analyzes were selected to quantitative analysis.

Strategies and search criteria
The search for articles of interest was performed in December 2022, using the reference academic search engines PubMed (PubMed.ncbi.nlm.nih.gov, accessed on 20 December 2022) and Web of Science (webofscience.com/wos/alldb/basic-search, accessed on 20 December 2022). To maximize the results and avoid losing potential articles of interest, a strategy focused on the generic terms was used. The terms “(Bisphenol) AND (Diabetes OR Hyperglycemia)” were used, without adding any restrictions in academic search engines. The search was carried out by three researchers independently (RMGT, MDM and ACC) and their decisions in each of the bibliographic search and evaluation steps were determined by consensus.

After removal of duplicate articles using the Mendeley bibliography manager (Mendeley Ltd., Elsevier, London, UK), the articles were evaluated by title/abstract. All the articles that were not original (such as reviews), in vitro or in vivo research models, exclusively BPA study models, or studies of compounds that were not BPs (such as phthalates), and all those articles that did not study DM, were excluded (Table 1). Subsequently, the full text of the manuscripts was analyzed and evaluated.

Selection of articles for qualitative and quantitative analysis
After the full-text analysis, a descriptive analysis of the selected articles was performed. In addition, relevant data for the qualitative study and subsequent quantitative analysis were extracted. All the studies that provided odds ratio (OR) and 95% confidence interval (CI) were selected. Studies that performed correlations, linear regressions, or multivariate analyzes were only included in the descriptive analysis. Discrepancies between independent reviews were resolved by consensus.

RMGT, MDM, ACC, CGC, NA, BJG, IH, RRC, LT and LB extracted the data for Tables 1 and 3; first author, year of publication, country, population group, number of individuals included, age, study period, type of study (Table 2), BP, biological fluid analyzed, analysis method, detection frequency, and metabolite concentration determined (Table 3).

Meta-analysis
Review Manager software (RevMan 5.3, Cochrane, London, UK) was used to perform the inverse variance method. An analysis was performed for each type of BP present in the literature (BPS, BPF and BPAF). Heterogeneity between studies was calculated by applying the $I^2$ and $P^2$ tests. The $P$ statistic was calculated as a percentage, and the results were interpreted as low, medium or high heterogeneity, reaching 25%, 50% and 75%, respectively[31]. The fixed-effect model was used when no heterogeneity was detected among studies, while the random-effect model was preferred when variance existed. $P < 0.05$ was considered statistically significant for all the analyses performed.

Risk of bias
The individual quality of the articles was evaluated considering the use of urinary creatinine or urine gravity as a normalization factor for glomerular filtration rate, and the use of covariates related to diabetes in the development of binomial and multinomial logistic regression models. For the evaluation of publication bias in the meta-analysis, funnel plots were used to identify symmetry or asymmetry in the distribution of results.

RESULTS

Selection of articles
The initial search identified 472 articles in PubMed and 816 in Web of Science. After exporting the set of references to the Mendeley desktop application and removing duplicates, a total of 928 items were obtained. The first analysis carried out
Table 1: Inclusion and exclusion criteria for the analysis of academic literature

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion criteria</td>
<td>Studies published in peer-reviewed journals</td>
</tr>
<tr>
<td></td>
<td>Studies published as original article accepted and published</td>
</tr>
<tr>
<td></td>
<td>Studies conducted in human populations, regardless of the population subgroup</td>
</tr>
<tr>
<td></td>
<td>Studies focused on bisphenols, except BPA</td>
</tr>
<tr>
<td>Exclusion criteria</td>
<td>Reviews, hypotheses, project reports, letters or comments</td>
</tr>
<tr>
<td></td>
<td><em>In vitro</em> or <em>in vivo</em> study models</td>
</tr>
<tr>
<td></td>
<td>Studies performed only on BPA, or on compounds other than bisphenols</td>
</tr>
<tr>
<td></td>
<td>Studies not developed in diabetes</td>
</tr>
</tbody>
</table>

BPA: Bisphenol A.

Table 2: Characteristics of included studies

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Country</th>
<th>Population group</th>
<th>N</th>
<th>Age</th>
<th>Study period</th>
<th>Type of study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kataria <em>et al</em>[32], 2017</td>
<td>USA</td>
<td>Healthy children</td>
<td>41 (19 males; 22 females)</td>
<td>10-13</td>
<td>2013-2014</td>
<td>Cross-sectional</td>
</tr>
<tr>
<td>Li <em>et al</em>[33], 2018</td>
<td>Saudi Arabia</td>
<td>Diabetic vs Control</td>
<td>54 (28 males and 26 females) vs 47 (20 males and 27 females)</td>
<td>28-68</td>
<td>2015-2016</td>
<td>Cross-sectional (case-control)</td>
</tr>
<tr>
<td>Duan <em>et al</em>[34], 2018</td>
<td>China</td>
<td>Diabetic vs Control</td>
<td>251 vs 251</td>
<td>D: 58 ± 10; C: 51 ± 10</td>
<td>2016-2017</td>
<td>Cross-sectional</td>
</tr>
<tr>
<td>Lee <em>et al</em>[36], 2019</td>
<td>Korea</td>
<td>Premenopausal adult women</td>
<td>459</td>
<td>20-48</td>
<td>2015-2016</td>
<td>Cross-sectional</td>
</tr>
<tr>
<td>Rancière <em>et al</em>[37], 2019</td>
<td>France</td>
<td>Diabetic vs Control</td>
<td>201 vs 584</td>
<td>30-65</td>
<td>1994-1996 + 3, 6 and 9 years</td>
<td>Longitudinal study</td>
</tr>
<tr>
<td>van der Meer <em>et al</em>[38], 2021</td>
<td>Netherlands</td>
<td>Subjects with impaired fasting glucose (i.e., fasted glucose 6.1 mmol/L to 7.0 mmol/L)</td>
<td>500 (299 males and 201 females)</td>
<td>53.4 ± 10.3</td>
<td>2009-2013 and 2014-2015</td>
<td>Longitudinal study</td>
</tr>
<tr>
<td>Tang <em>et al</em>[39], 2023</td>
<td>China</td>
<td>GDM vs non-GDM pregnant women</td>
<td>100 vs 400</td>
<td>30.62 ± 6.46 vs 30.60 ± 6.41</td>
<td>From 2015</td>
<td>Cross-sectional (case-control)</td>
</tr>
<tr>
<td>Lee <em>et al</em>[40], 2021</td>
<td>USA</td>
<td>Diabetes-free women</td>
<td>1299</td>
<td>45-56</td>
<td>1999-2000, 2002-2003</td>
<td>Longitudinal study</td>
</tr>
<tr>
<td>Duan <em>et al</em>[41], 2021</td>
<td>China</td>
<td>Diabetic vs Control</td>
<td>60 vs 60</td>
<td>56 ± 7 vs 56 ± 7</td>
<td>2016-2017</td>
<td>Cross-sectional (case-control)</td>
</tr>
<tr>
<td>Moreno-Gómez-Toledano <em>et al</em>[43], 2022</td>
<td>USA</td>
<td>General population</td>
<td>3658 (641 diabetic)</td>
<td>Non-D: 41.11; D: 58.33</td>
<td>2013-2016</td>
<td>Cross-sectional</td>
</tr>
<tr>
<td>Zhu <em>et al</em>[44], 2022</td>
<td>USA</td>
<td>GDM vs non-GDM pregnant women</td>
<td>333</td>
<td>31.2 ± 4.6</td>
<td></td>
<td>Cross-sectional (case-control)</td>
</tr>
</tbody>
</table>

D: Diabetes; C: Control; GDM: Gestational diabetes mellitus.

Based on the title and abstract eliminated 884 articles that did not meet the selection criteria, yielding a total of 44 articles. From them, 13 manuscripts that met the search criteria were selected for qualitative analysis, and six were finally included in the quantitative analysis. As can be seen in Figure 1, the rest of the academic papers corresponded to reviews or project reports (n = 12), studies of BPA or compounds not related to BPs (n = 12), pathologies other than diabetes (n = 6) and an *in vitro* study. The degree of novelty of the topic is reflected in the temporality of the 13 selected articles, published from 2017 to 2022.
Table 3 Quantitative data of bisphenols analyzed

<table>
<thead>
<tr>
<th>Biological fluid</th>
<th>Bisphenol analyzed</th>
<th>Analysis method</th>
<th>Detection frequency (%)</th>
<th>GM (95%CI)/median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine</td>
<td>BPS/BPF</td>
<td>HPLC-MS/MS</td>
<td>-</td>
<td>2.06 (1.56-2.69)/0.141(0.141-0.141)</td>
</tr>
<tr>
<td>Urine</td>
<td>BPF/BPS/BPAP</td>
<td>HPLC-MS/MS</td>
<td>D: 81.5/15.9/0.0; C: 48.9/0.0/17.0</td>
<td>D: 3.6/0.10/0.05</td>
</tr>
<tr>
<td>Urine</td>
<td>BPS/BPAF/BPF</td>
<td>HPLC-MS/MS</td>
<td>D: 68.1/57.4/26.3; C: 47.8/39.4/37.1</td>
<td>D: 0.199 (ND-0.56)/0.093 (ND-0.84)/ND (ND-0.12); C: ND (ND-0.25)/ND (ND-0.05)/ND (ND-0.23)</td>
</tr>
<tr>
<td>Urine</td>
<td>BPS/BPAF/BPF</td>
<td>UHPLC-TQMS</td>
<td>90.06/42.59/94.72</td>
<td>0.36 (0.33, 0.38)/0.030 (0.028, 0.031)/2.01 (1.75, 2.32)</td>
</tr>
<tr>
<td>Urine</td>
<td>BPS/BPF/BPB/BPAP</td>
<td>HPLC-MS/MS</td>
<td>D: 83.7/3.7/1.3/4.8</td>
<td>0.08 (0.03-0.24)/-/-/-</td>
</tr>
<tr>
<td>Urine</td>
<td>BPS-glucuronide</td>
<td>HPLC-MS/MS</td>
<td>Baseline: 14; year 3:9</td>
<td>&lt; LOD (&lt; LOD-&lt; LOD)</td>
</tr>
<tr>
<td>Urine</td>
<td>BPS/BPF</td>
<td>LC-MS/MS</td>
<td>Baseline: 73.7; follow-up: 80.6</td>
<td>Baseline: 0.99 (2.86); follow-up: 1.11 (2.64)</td>
</tr>
<tr>
<td>Urine</td>
<td>BPS/BPF/BPAF</td>
<td>HPLC-MS/MS</td>
<td>D: 66.7/31.7/45.0; C: 40.0/40.0/41.7</td>
<td>D: 0.21 (ND-0.35)/ND (ND-0.23)/ND (ND-0.15); C: ND (ND-0.23)/ND (ND-0.31)/ND (ND-0.05)</td>
</tr>
<tr>
<td>Urine</td>
<td>BPS/BPF</td>
<td>HPLC-MS/MS</td>
<td>88.4/57.1</td>
<td>D: 0.59 (0.53-0.64)/0.43 (0.38-0.48); C: 0.50 (0.48-0.52)/0.41 (0.39-0.43)</td>
</tr>
<tr>
<td>Urine</td>
<td>BPS/BPF</td>
<td>HPLC-MS/MS</td>
<td>75.1-90.0/-</td>
<td>0.497 (0.436-0.559)/not calculated1</td>
</tr>
</tbody>
</table>

1Not calculated because the proportion of results below limit of detection was too high to provide a valid result.

BPS: Bisphenol S; BPF: Bisphenol F; BPAF: Bisphenol AF; BPAP: Bisphenol AP; BPB: Bisphenol B; HPLC-MS/MS: High-performance liquid chromatography and tandem mass spectroscopy; UHPLC-TQMS: Ultra-high-performance liquid chromatography with triple quadrupole mass spectrometry; LC-MS/MS: Offline isotope dilution liquid chromatography tandem mass spectrometry; D: Diabetes; C: Control; ND: Not Detectable; LOD: Limit of detection.

Figure 1 Schematic representation of the methodology used based on The PRISMA Statement. BPA: Bisphenol A.
Qualitative analysis – genealogy of the paradigm

From a chronological point of view, the first work of interest was Kataria et al[32], published in 2017 (see Table 2 for qualitative manuscript details). The authors studied urinary BPs (BPA, BPS and BPF), and blood glucose and insulin levels in a small cohort of children aged 10–13 years. Subsequently, multivariate regression analysis of overweight, body mass index (BMI), insulin resistance, and albumin to creatinine ratio (ACR) showed only significant differences between BPS and ACR. In conclusion, the authors stated that BPS exposure was associated with renal function, but neither BPS nor BPF were related to DM.

In 2018, the first significant evidence between the new substitutes for BPA and DM in human populations appeared: Li et al[33] and Duan et al[34]. Li et al[33] observed a significant relationship between BPF and DM risk in an adult human cohort from Saudi Arabia. In the multinomial logistic regression model performed between quartile 4 (Q4) versus Q1 of BPF, corrected for creatinine, using age, gender, nationality, smoking status, and occupation as covariates, an OR (95% CI) of 8.02 (1.68–38.3) was observed. Due to the low presence of BPS and BPAF, they did not develop statistical association models with the BPA derivatives (Table 3). Duan et al[34] only observed statistically significant results for urinary BPS and BPAF. They performed binomial logistic regression analyzes for DM in a cohort of 251 DM patients versus 251 controls. After correcting for urinary creatinine and including the covariates sex, age, BMI, smoking and alcohol consumption, exercise status, education level, family history of DM, and blood pressure, an OR (95% CI) of 1.73 (1.37–2.18) for BPS and 4.95 (3.15–7.79) for BPAF was obtained.

In 2019, three articles relevant to the context of this manuscript were published: Zhang et al[35], Lee et al[36] and Ranciére et al[37]. The studies were conducted in pregnant women, premenopausal adult women, and in the general population. Zhang et al[35] observed a significant association between BPAF and risk of gestational DM (GDM) in pregnant women with healthy BMI, determining an OR (95% CI) of 1.70 (1.03–2.72). The authors normalized the values of urinary metabolites correcting with specific gravity. Additionally, the logistic regression models performed in women with normal or high BMI, were corrected with the covariates maternal age, pre-pregnancy BMI, educational levels, parity, passive smoking and fetal sex. Lee et al[36] performed multipollutant models. The results showed a significant relationship between urinary BPS and the homeostasis model assessment for insulin resistance (HOMA-IR), reaffirming the possible relationship between BPS and DM. Finally, Ranciére et al[37], in a 9-year longitudinal study carried out in the DESIR cohort, associated the glucuronidated form of BPS (BPS-G) with an increased risk of DM. Due to the small number of samples with the presence of BPS-G, they subdivided the population between the presence or absence of BPS-G, obtaining a hazard ratio value (95% CI) of 2.81 (1.74–4.53).

In 2021 five articles relevant to the analysis were published: van der Meer et al[38], Tang et al[39], Lee et al[40], Duan et al[41] and An et al[42]. van der Meer et al[38] analyzed the presence of endocrine-disrupting metabolites in the urine of subjects with impaired fasting glucose levels (6.1–7.0 mmol/L). The authors collected two samples per individual in two different times (first sample 2009–2013; second sample 2014–2015) and investigated the BP metabolite excretion over time both within and between individuals. Interestingly, while BPA median concentrations decreased (50% reduction), BPF levels remained stable within individuals and over time. BPS was detected only in 18% of the samples, so it was excluded from subsequent analysis. Tang et al[39] performed a case–control study in pregnant women with and without GDM. Multinomial logistic regression models performed with serum BPS and BPF, corrected for pregnancy BMI, area of residence, passive smoking during pregnancy, gravity, parity, and exercise regularly, showed positive but nonsignificant results, with OR (95% CI) of 1.68 (0.95–2.99) for highest levels of BPS, and 1.18 (0.68–2.05) for BPF. Lee et al[40] analyzed urinary BPF in a longitudinal study with 1299 nondiabetic women (45–56 years) and were followed 3 years later. Individual phenols were examined using Cox regression, and the overall joint effects using quantile-based g-computation. The results showed no significant associations between BPF and DM in middle-aged women. Duan et al[41] published a new case–control study in 60 type 2 DM patients and 60 controls, matched by age, sex and BMI. They observed a significant association between BPAF and risk of gestational DM (GDM) in pregnant women, premenopausal adult women, and in the general population. Moreno-Gómez-Toledano et al[43] and Zhu et al[44] published two retrospective cohort studies, in the general population and pregnant women, respectively. In the Moreno-Gómez-Toledano et al[43] study, urinary BPS and BPF, corrected with creatinine, were analyzed using binomial and multinomial logistic regression models, corrected by age, sex, BMI, smoking, hypertension, and DM. For the urinary BPS, the results were 1.099 (1.016–1.188), OR (95% CI) in the binomial, and 1.28 (0.99–1.67) in the multinomial analysis. Urinary BPS showed OR of 0.991 (0.928–1.059) and 0.92 (0.70–1.20), respectively. Zhu et al[44] did not analyze BPF because the proportion of results below the limit of detection (LOD) was too high to provide a valid result. Urinary BPS was analyzed through multinomial logistic regression models, adjusted for urinary creatinine levels, age, pre-pregnancy BMI, and race/ethnicity (White, Black, Hispanic, and other). The results showed an OR (95% CI) in Asian/Pacific Islanders (A/PIs) of 2.12 (1.0–4.5) and 4.60 (1.55–13.7) in non-A/PIs.

Meta-analysis

As previously detailed, the BPA substitutes–diabetes paradigm comprises a small number of heterogeneous but potentially significant publications.
Figure 2 Meta-analysis. A and B: Meta-analysis (inverse variance method) of the publications that studied bisphenol S and diabetes in humans (A), and funnel plot (for publication bias) (B). 95%CI: 95% confidence interval; BMI: Body mass index.

**BPS**

For the BPS meta-analysis, the works of Duan et al[34], Zhang et al[35], Tang et al[39], Zhu et al[44] and Moreno-Gómez-Toledano et al[43] were used. For the combined analysis, binomial and multinomial logistic regression analyses of the different population groups were selected, including a total of eight elements in the meta-analysis. In the work of Zhu et al[44], the population was subdivided into two differentiated groups: A/PIs and non-A/PIs. In Zhang et al[35], pregnant women with normal pre-pregnancy BMI (18.5–23.0) and high pre-pregnancy BMI (23–28) were included. Finally, in the work of Moreno-Gómez-Toledano et al[43], binomial and multinomial logistic regression model analyses were performed with a multiethnic American cohort of adult individuals.

The results of the combined analysis, as can be seen in Figure 2, showed a moderate heterogeneity, ($I^2 = 59$%). The combined odds ratio was 1.35 (1.08–1.70), with a highly significant $P = 0.008$. The positive and significant results increased the strength of the evidence that BPS could be an environmental factor that could be related to DM.

**BPF**

Articles with relevant data for qualitative analysis were Zhang et al[35], Tang et al[39], Moreno-Gómez-Toledano et al[43] and Li et al[33]. The same subgroups used in the quantitative analysis of the BPS were included, in addition to the multinomial logistic regression performed in the case–control study by Li et al[33]. The results did not show a significant combined result, although they showed a positive trend with DM (Figure 3). Except for the work of Li et al[33], none of the other study models showed a significant relationship between BPF and DM, which agrees with the result of the combined model. The $I^2$ of 51% and combined odds ratio of 1.10 (0.85–1.41), with $P = 0.47$, showed the moderate heterogeneity of the studies and confirmed that there was no evidence to connect BPF with DM.

**BPAF**

The third most widely used BP is the one with the least amount of evidence in the literature. As can be seen in Figure 4, three population groups from Duan et al[34] and Zhang et al[35] were included. $I^2$ showed a high degree of heterogeneity (89%). The combined result (2.06; 0.83–5.15) showed a positive trend with DM, but due to the small amount of evidence and the absence of a significant result, it was concluded that it is necessary to increase the number of studies to explore the possible implications of BPAF for the risk of development or progression of DM.
Publication bias

Despite the moderate degree of heterogeneity of the studies included in the quantitative analyzes of BPS and BPF, the funnel plots showed symmetry, as can be seen in Figures 2 and 3. In the case of the BPAF, there was insufficient evidence. As can be seen in Figure 4, it is essential to increase the number of studies related to the BPAF–diabetes paradigm.

DISCUSSION

The present study was the first systematic review and meta-analysis of the new emerging bisphenols–diabetes paradigm. The systematic analysis of the literature has identified 13 studies with evidence for the context of the study in humans. The detailed analysis of the genealogy of the paradigm provided qualitative and quantitative data, which were used for the subsequent meta-analysis for each of the three most widely used BPA substitutes used in the plastic industry.

The new BPA substitute molecules retain a similar structure, with the presence of two phenolic rings. The monomers only differ in their interphenolic linker, characterized by the presence of sulfur in BPS, fluorine in BPAF, and the absence of methyl groups (CH₃) in BPF [25,45]. Possibly due to their structural homology, there is evidence that suggests similarities in the hormonal activity of the new BPs [22]. In wild-type mice, Marroqui et al [46] observed that treatment with BPS and BPF rapidly increased insulin release and decreased ATP-sensitive K⁺ channel activity. In contrast, treatment in beta estrogen receptor knockout (BERKO) mice did not cause DM-related changes. For BPAF, Wei et al [47] demonstrated an important relationship with the development of DM in zebrafish (Danio rerio) exposed to environmentally relevant concentrations of the phenolic molecule. Animals exposed to µg/L doses suffered a significant increase in fasting blood glucose levels, hepatic glycogen content, and hepatosomatic indexes, and decreased muscular glycogen content. In addition, they observed alterations in insulin regulation, and quantitative PCR revealed alteration of genes involved in glycometabolic networks, which might promote hepatic gluconeogenesis and inhibit glycogenesis and glycolysis in the muscle and/or liver.

The quantitative results of the meta-analysis showed that the evidence analyzed in the literature related to BPS and DM showed a positive and significant relationship. There was a moderate degree of heterogeneity between studies and the symmetrical pattern observed in the funnel plot added robustness to the combined analysis. The OR (95% CI) of 1.35 (1.08–1.70), with a P value of 0.008 confirmed the qualitative evidence described in the qualitative analysis. However, BPF showed a positive trend, but did not show a significant result. Similarly, in the case of the BPAF, probably due to the small amount of evidence available, a significant result (although markedly positive) was not obtained either.
There were two examples in the literature that pointed to BPS as a potentially more dangerous monomer than BPA, because there was alarming evidence related to the pharmacokinetics and biodegradability of BPS. Gayrard *et al* [48] observed that the bioavailability of BPS was 250 times greater than BPA in a porcine study model, and Danzl *et al* [49] demonstrated that BPA and BPF were biodegradable in the marine environment; a phenomenon that does not occur with BPS.

Duan *et al* [41] (described in the qualitative analysis), observed metabolome alterations in a cohort of 60 patients with DM and 60 control subjects. Cohort analysis revealed a significant association (linear regression models) between BPS and pyridoxal 5’-phosphate (PLP). PLP deregulation has been linked to DM and blood glucose regulation. In addition, PLP may improve insulin sensitivity by controlling expression of the gene related to adipogenesis [41]. Metabolome analysis also revealed a significant association between BPAF and pyridoxal, L-histidine and L-citrulline. Histidine supplementation has been shown to be effective for insulin resistance, plasma lipid levels, and inflammatory markers, and delayed the development of atherosclerosis in several rodent models of diaDMabetes and metabolic syndrome [50]. Furthermore, citrulline is involved in the production of nitric oxide by nitric oxide synthase, and it plays a crucial role in DM [51], since it is a strong vasodilatory and anti-inflammatory signaling molecule that plays diverse roles in maintaining vascular homeostasis [52].

**CONCLUSION**

The body of evidence analyzed in this study revealed interesting relationships between the new BPA substitute molecules and DM. The quantitative results showed a positive relationship with BPS, BPF and BPAF, which was only significant with BPS. The present work revealed the small amount of scientific evidence related to the paradigm in the human context, as well as the need to deepen the study of the emerging BPA substitute molecules. Our results suggest the need to apply the precautionary principle, regulating the use of new BPs. In conclusion, replacing BPA with molecules such as BPS, BPF or BPAF is unlikely to protect the population from potential health risks, such as DM.

**ARTICLE HIGHLIGHTS**

**Research background**

Diabetes mellitus (DM) is one of the largest global health emergencies of the 21st century. The prevalence of DM has
increased substantially, from 108 million adults in 1980 to 536 million. In parallel, the consumption of plastic products has increased substantially in recent decades, which implies chronic exposure to monomers, such as bisphenol (BP)A, or its new substitute molecules, BPS, BPF and BPAF.

**Research motivation**
In recent years, the relationship between BPA and DM has been demonstrated. The new BPA substitute molecules have high structural homology with BPA, as well as similar hormonal activity. Therefore, the study of new BPs is potentially linked to population health.

**Research objectives**
The present systematic review of the literature allowed a coherent evaluation of the state of the art of the new bisphenols–diabetes paradigm. Subsequently, a meta-analysis was performed to unify the existing quantitative data in human cohorts.

**Research methods**
Using the PRISMA guidelines as a reference, a systematic review of the literature was carried out. Using the qualitative data, a chronological review was performed, and all quantitative data of interest were identified. Subsequently, a meta-analysis was performed for each BP identified using the RevMan software, and a funnel plot was also performed for risk of bias.

**Research results**
Qualitative analysis identified 13 recently published articles (2017–2022) that contextualized the new evidence between emerging BPs and DM. The subsequent meta-analysis showed positive results with the three BPs, but only BPS was significant.

**Research conclusions**
The present study was the first systematic review and meta-analysis of the new BPA substitute molecules and DM. The results support the possible positive relationship between the new BPs and the risk of DM, especially with BPS. Consequently, the substitution of BPA may not improve population health, and government institutions should consider applying the precautionary principle.

**Research perspectives**
The results support the need to deepen the paradigm, increasing the evidence in basic and translational research, to determine the real risk to which the human population is exposed.

**ACKNOWLEDGEMENTS**
We want to thank Rosalia Gómez-Toledano (philologist and English teacher for 37 years) for proofreading the manuscript.

**FOOTNOTES**

**Author contributions:** Moreno-Gómez-Toledano R contributed to conceptualization; Moreno-Gómez-Toledano R, Delgado-Marín M, Cook-Calvete A contributed to the systematic review; Moreno-Gómez-Toledano R, González-Cucharero C, Alcharani N, Jiménez-Guirado B, Hernández I, Ramírez-Carracedo R, Tesoro L, Botana L, Sánchez-Esteban S, and Diez-Mata J contributed to the qualitative analysis; Moreno-Gómez-Toledano R contributed to data curation, formal analysis, methodology, and writing the original draft; Saura M, Zaragoza C, Bosch RJ, and Zamorano JL contributed to funding acquisition; Moreno-Gómez-Toledano R, Delgado-Marín M, Cook-Calvete A, González-Cucharero C, Alcharani N, Jiménez-Guirado B, Hernández I, Ramírez-Carracedo R, Tesoro L, Botana L, Sánchez-Esteban S, and Diez-Mata J contributed to the investigation; Saura M, Zaragoza C, Bosch RJ, and Zamorano JL contributed to project administration; Moreno-Gómez-Toledano R, Saura M, Zaragoza C, Bosch RJ, and Zamorano JL contributed to writing and editing the review; and all authors have read and agreed to the published version of the manuscript.

**Supported by** the “Margarita Salas” postdoctoral fellowship from the Universidad de Alcalá; and FPI fellowships from the Universidad de Alcalá.

**Conflict-of-interest statement:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to
The research article discusses the relationship between new emerging bisphenols and diabetes, highlighting the importance of understanding their effects and implications. The article references several studies that explore various aspects of diabetes, bisphenol A (BPA), and other environmental factors. These references cover topics from epigenetic changes induced by in utero BPA administration to the role of bisphenols in diabetes and cardiovascular disease in male and female offspring. The research underscores the need for further investigation into the mechanisms of these effects and the broader implications for public health.
N. Oral Systemic Bioavailability of Bisphenol A and Bisphenol S in Pigs. 


Holeček M. Histidine in Health and Disease: Metabolism, Physiological Importance, and Use as a Supplement. Nutrients 2020; 12 [PMID: 32235743 DOI: 10.3390/nu12030848]
